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Purpose: To prospectively determine cancer yield, callback and bi-
opsy rates, and positive predictive value (PPV) of mam-
mography, magnetic resonance (MR) imaging, and ultra-
sonography (US) in women at high risk for breast cancer.
Materials and
Methods:
The study was approved by the institutional review board
and was HIPAA compliant, and informed consent was
obtained. We conducted a prospective pilot study of
screening mammography, MR, and US in asymptomatic
women 25 years of age or older who were genetically at
high risk, defined as BRCA1/BRCA2 carriers or with at
least a 20% probability of carrying a BRCA1/BRCA2 mu-
tation. All imaging modalities were performed within 90
days of each other. Data were analyzed by using exact
confidence intervals (CIs) and the McNemar test.
Results: A total of 195 women were enrolled in this study over a
6-month period, and 171 completed all study examinations
(mammography, US, and MR). Average age of the 171
participants was 46 years  10.2 (standard deviation).
Sixteen biopsies were performed and six cancers were
detected, for an overall 3.5% cancer yield. MR enabled
detection of all six cancers; mammography, two; and US,
one. The diagnostic yields for each test were 3.5% for MR,
0.6% for US, and 1.2% for mammography. MR, US, and
mammography findings prompted biopsy in 8.2%, 2.3%,
and 2.3% of patients, respectively. None of the pairwise
comparisons were statistically significant. The PPV of bi-
opsies performed as a result of MR was 43%.
Conclusion: Screening MR imaging had a higher biopsy rate but helped
detect more cancers than either mammography or US. US
had the highest false-negative rate compared with mam-
mography and MR, enabling detection of only one in six
cancers in high-risk women.
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Genetic predisposition accounts foran estimated 5%–10% of allbreast cancers and leads to a min-
imum of 10 000 new breast cancer
cases diagnosed in the United States
each year (1,2). Counseling women who
are at high risk for breast cancer is chal-
lenging. Although there are increasing
data demonstrating that prophylactic
surgery (mastectomy and oophorec-
tomy) can reduce the risk of breast and
ovarian cancer (3–8), the potential ab-
solute benefits must be balanced against
issues of body image, the impact of hor-
mone replacement therapy, and options
for enhanced surveillance and chemo-
prevention (9–11). Most experts sug-
gest aggressive surveillance consisting
of a mammogram and physical examina-
tion every 6–12 months beginning at
age 25 to 35. However, scarce data exist
to indicate that such aggressive mam-
mographic screening of this population
affects breast cancer mortality. In addi-
tion, mammographic sensitivity is lower
in young women and in women with
dense breast tissue. Given the younger
age of onset of cancer in women at high
risk (50% of women with a BRCA1 mu-
tation develop breast cancer by the age
of 50) (12), it is worrisome that screen-
ing mammography alone may be insuffi-
cient to detect breast cancer at an early
stage in this patient population.
Because of preliminary but consis-
tent published reports from multiple in-
vestigators in the United States, Can-
ada, and Europe supporting the added
benefit of magnetic resonance (MR) im-
aging and ultrasonography (US) in de-
tecting cancer in women at high risk,
the American Cancer Society currently
suggests that women discuss with their
clinicians the potential benefits and
risks of adding alternative screening
methods such as US or MR to comple-
ment mammographic screening (13). In
2003, after thorough review of the liter-
ature, several third-party payers agreed
to reimburse for screening MR imaging
in women at high risk for breast cancer
(14–16).
Few prior studies have included
both US and MR for the detection of
clinically and mammographically occult
cancer in women at high risk, and the
combined range of added cancer yield
by using both modalities varies widely
from less than 1% to greater than 10%.
Thus, the purpose of our study was to
prospectively determine cancer yield,
callback and biopsy rates, and positive
predictive value (PPV) of mammogra-
phy, MR imaging, and US in women at
high risk for breast cancer.
Materials and Methods
The International Breast MRI Consortium
and Cancer Genetics Network
This study was conducted by the Inter-
national Breast MRI Consortium (IBMC)
in collaboration with the Cancer Genet-
ics Network (CGN). The IBMC was de-
veloped and supported by the National
Cancer Institute and the Office of Wom-
en’s Health to evaluate the role of MR in
breast cancer. Since its inception, the
consortium has conducted two large
multicenter studies. Research institu-
tions and community hospitals and clin-
ics from the United States, Canada, and
Europe participate. The CGN is a na-
tional network of centers specializing in
the study of inherited predisposition to
developing cancer (17). CGN supports
studies on the genetic basis of human
cancer susceptibility and the integra-
tion of this information into medical
practice. The gadolinium-based con-
trast agents used in the study were
provided by GE Healthcare (Wauke-
sha, Wis) and Bracco Diagnostics (Mi-
lan, Italy). The authors had full control
of the data and information submitted
for publication.
Study Participants
Six facilities located throughout the
United States participated in this IBMC/
CGN study. All facilities obtained ap-
proval to participate from their institu-
tional review boards, and written in-
formed consent was obtained from all
participants prior to entering the study.
The study was Health Insurance Porta-
bility and Accountability Act compliant.
Women were deemed eligible to partic-
ipate in the study if they were 25 years
of age or older and identified as geneti-
cally high risk. A woman was deter-
mined to be high risk if she met any of
the following criteria:
1. Tested positive for BRCA1/
BRCA2 mutation or had a first- or sec-
ond-degree relative who tested positive
for either mutation;
2. The probability of carrying a





CGN  Cancer Genetics Network
CI  confidence interval
IBMC  International Breast MRI Consortium
PPV  positive predictive value
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Advance in Knowledge
 Screening MR allowed detection
of more cancers (n  6) in high-
risk women compared with
screening US (n  1) and/or
screening mammography (n  2).
Implications for Patient Care
 Women at high risk for breast
cancer can benefit from screening
MR imaging.
 Women at high risk for breast
cancer who undergo MR do not
show benefit from screening US.
 In counseling high-risk women
who are considering screening
MR, the benefits include a pre-
dicted added cancer yield of 23
cancers per 1000 women screened
with MR, and the risk of false-
positives includes less than 5% of
women undergoing biopsy result-
ing in a benign outcome.
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history of breast and ovarian cancer)
was found to exceed 20%, as deter-
mined with BRCAPRO (18);
3. The family contained at least two
instances of ovarian or breast cancer
among the participant and first- or sec-
ond-degree relatives within the same
lineage (multiple primary cancers within
same person met criteria); or
4. The woman was of Ashkenazi
Jewish ethnicity with one first- or two
second-degree relatives with breast or
ovarian cancer or was Ashkenazi Jewish
and had breast cancer. Where breast
cancer was required to meet criteria,
participant age of diagnosis of at least
one of the breast cancers must have
been premenopausal or less than 50
years old.
Women were excluded on the basis
of the following criteria:
1. Known contraindication to MR:
pregnancy, pacemaker, magnetic aneu-
rysm clip or other implanted magnetic
device, or severe claustrophobia;
2. Current palpable or mammo-
graphic-actionable finding known at
time of enrollment assessment (benign
findings at mammography or physical
examination allowed);
3. Prior biopsy in the study breast
within the past 6 months (including fine-
needle aspiration);
4. Received adjuvant chemotherapy
or radiation therapy within 6 months of
study entry (may have been receiving
tamoxifen or aromatase inhibitor either
as adjuvant hormonal therapy or for
preventive measures);
5. A first- or second-degree relative
with a BRCA1/BRCA2 mutation and the
potential participant tested negative for
the same mutation;
6. Current untreated malignancy
(other than nonmelanoma skin cancer);
7. Metastatic malignancy within the
past 5 years; and
8. A psychiatric condition prevent-
ing fully informed consent.
Data Collection
All sites collected data by using study
forms and submitted the data by means
of Web site entry to the American Col-
lege of Radiology. Quality-control pro-
cedures included review of each submis-
sion to identify critical missing forms or
data. The American College of Radiol-
ogy provided routine reports to each
participating institution to identify par-
ticipants with missing information and
to clarify inconsistencies in information.
Clinical history.—Study participants
were seen in a cancer risk evaluation
program where a pertinent history and
physical examination were performed
prior to study entry. Demographic infor-
mation and a thorough medical history,
including genetic testing, hormonal medi-
cations, family and personal history of
breast disease, obstetric history, phase of
menstrual cycle, and results of prior
breast cancer screening, were collected.
Study procedures.—All patients un-
derwent a clinical breast examination,
mammography, US, and MR imaging as
part of the study. Study protocol speci-
fied all examinations be performed
within 90 days of each other. Because
the radiologists conducting US had di-
rect contact with the patient during the
examination, US was performed prior
to the MR and the study mammographic
examinations to reduce potential con-
tamination of the US examination with
information from the mammogram or
MR images. The MR, mammographic,
and US images were interpreted with-
out knowledge of the results of the other
modalities at the host institution. Sepa-
rate readers were assigned for each ex-
amination to ensure blinded readings.
Study protocol required all suspicious
findings to be acted on. Fifteen readers
participated in the study. All mammog-
raphers and US readers were Mammog-
raphy Quality Standards Act certified.
All MR image readers were trained in
imaging and qualitative kinetic features
and had at least 2 years experience in-
terpreting MR images prior to partici-
pating in this study.
All study participants underwent a
two-view mammographic study of each
Figure 1
Figure 1: Flow chart shows enrollment, eligibility, and study findings.
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breast consisting of a craniocaudal and
a mediolateral oblique view. Spot mag-
nification was used as needed. All mam-
mograms were coded according to the
American College of Radiology Breast
Imaging and Reporting Data System
(ACR BI-RADS) lexicon, including breast
composition, findings, and overall assess-
ment (19). The overall assessment was
performed according to a five-point scale
as indicated in the ACR BI-RADS lexicon
(1  negative, 2  benign, 3  probably
benign, 4  suspicious abnormality, 5 
highly suggestive of malignancy).
US examinations were conducted
by using high-frequency high-resolution
techniques with 8-mHz or greater trans-
ducers. The entire breast was scanned
in two planes by an experienced radiol-
ogist. Special emphasis was directed to-
ward areas in the breast periphery that
often are not well-studied with mammog-
raphy, including the regions of the infra-
mammary fold, medial breast, far lateral
breast, and infraclavicular portions of
the breast. The ACR BI-RADS lexicon
for US was used to report findings.
The MR examination protocol in-
cluded 1.5-T magnet strength, a dedi-
cated breast coil, and the following se-
quences: precontrast sagittal T2-weighted
(repetition time msec/echo time msec,
4000/80; matrix, 256  256) fast spin
echo images with fat suppression, and
both pre- and postcontrast sagittal T1-
weighted (50/4.5; matrix, 256  128;
sections, 32–60) three-dimensional gra-
dient-echo images with a 60° flip angle.
Field of view was restricted to 16–18 cm
over the breast depending on patient size,
and sections were 3 mm thick or less.
T1-weighted images were acquired prior
to and immediately following bolus injec-
tion of contrast–enhanced material (0.1
mmol/kg gadolinium [0.1 mmol/kg  0.2
mL/kg] gadolinium).
Any suspicious MR-enhanced le-
sions were described based on lesion
shape, borders, distribution, kinetics,
and internal architecture. The final MR
assessment was classified on a five-point
scale (1  negative, 2  benign, 3 
probably benign, 4  suspicious abnor-
mality, 5  highly suggestive of malig-
nancy). Examinations given an initial as-
sessment of incomplete or 0 received a
final MR assessment of 1–5 based on
results of follow-up procedures. A le-
sion was identified as suspicious if there
was a focal mass with irregular or spic-
ulated margins, if enhancement was in a
ductal distribution, if a solid lesion
showed rim enhancement, or if there
was intense regional enhancement in
less than one quadrant. Benign lesions
were identified as having smooth or lob-
ulated margins with internal septations,
or if the mass was cystic. Reference
standard information about cancer sta-
tus was obtained for cases that had a
positive result in one of the modalities
under investigation and went on to have
a biopsy performed. Because the pri-
mary outcomes of this study were can-
cer yield, callback and biopsy rates, and
PPV of biopsies performed, the study
design did not include additional fol-
low-up (eg, 12- or 24-month follow-up)
information about the patients.
Statistical Analysis
Data were analyzed under the direction
of the Center for Statistical Sciences at
Brown University, which served as the
Biostatistics Center for all IBMC trials.
Data were prospectively monitored in
a collaborative effort with IBMC data
management located at the American
College of Radiology. Statistical soft-
ware SAS (version 8.0; SAS, Cary, NC)
and Stata (version 7.0; Stata, College
Station, Tex) were used to process the
data and facilitate statistical analyses.
For purposes of computing the diag-
nostic yield of an imaging modality, test
results were dichotomized as negative
(category 1 or 2) or positive (categories
3, 4, or 5). Invasive cancer and ductal
carcinoma in situ were classified as ma-
lignant; all other pathologic findings
were classified as not malignant. For
this study, callback or positive examina-
tion rates were computed as the per-
centages of participants who had a test
Figure 2
Figure 2: Negative screening mammogram and US of 46-year-old woman. Sagittal precontrast (A, T2-
weighted fast spin-echo with fat suppression) and postcontrast (B, T1-weighted gradient-echo with fat sup-
pression) images demonstrate 8  3  3 linear focus of enhancement in left breast (C) (arrow). Pathologic
report proved infiltrating ductal carcinoma.
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result in category 3, 4, or 5. Biopsy
rates based on a positive examination
were computed as the percentages of
participants who had a biopsy performed
based on a positive examination. PPVs
of biopsies performed were computed
as the percentage of participants diag-
nosed with cancer after a biopsy.
Exact confidence intervals (CIs)
were computed for each test perfor-
mance measure. Rates were compared
using the McNemar test to account for
the paired nature of the design. CIs for
rate differences were obtained by invert-
ing the McNemar test results. A P value of
.05 was utilized to define statistical signif-
icance. Computations were performed
using SAS and Stata subroutines.
Results
Participants
One hundred ninety-five women were
enrolled in this study during a 6-month
period from November 2002 to April
2003. Two women were later found to
not meet eligibility criteria, one under-
went screening US after MR, and two
were found ineligible because the length
of time between study procedures was
greater than 90 days. Of the remaining
190 women, seven did not undergo
mammography, 11 did not undergo MR,
and one withdrew her consent. The re-
maining 171 had evaluable assessments
for all examinations and comprised the
analysis group for this study (Fig 1).
Patient characteristics of the 190 eligi-
ble women and the 171 women included
in analysis showed no substantial differ-
ences between the two groups (Table 1).
Genetic Testing, Cancers
Ninety-one of 171 women included in
the analysis group had genetic testing
for possible familial cancer risk. Thirty-
seven women were found to be positive
for a BRCA1 mutation and 36 were pos-
itive for a BRCA2 mutation. The mean
age of the patients was 46 years; nearly
one-half (45.6%) were premenopausal
while another 52 (30.4%) entered into
menopause due to surgery. The major-
ity (84.8%) of the participants reported
some history of hormone use. Over
65% of the women had heterogeneously
or extremely dense breasts. More than
one-third of the study participants had
prior benign biopsy and one-fourth had
a prior diagnosis of breast cancer.
Six cancers were detected among
the 171 study participants. Of these,
mammography enabled detection of
two (33%) cancers; US, one (17%); and
MR, six (100%). All six cancers were
infiltrating ductal carcinomas (Table 2).
One-half of the participants with a de-
tected cancer were positive for BRCA1/
BRCA2. Two of six (33%) participants
diagnosed with cancer had scattered fi-
broglandular breast density, three (50%)
had heterogeneously dense breast tissue,
and one (17%) had extremely dense
breast tissue. The four cancers in women
with heterogeneously dense and ex-
tremely dense breast tissue were only
detected at MR (Table 2, Fig 2).
MR, US, and Mammography
MR resulted in more patients being re-
called for additional imaging or biopsy
(24%) compared with mammography
(10%) or US (9%) alone (Table 3). MR
resulted in 8.2% of women undergoing
biopsy compared with 2.3% for mam-
mography and 2.3% for US. The PPVs
of biopsies obtained by using MR (43%)
and mammography (50%) were higher
than those of US (25%). Of the four
cancers identified by MR alone, one was
removed for biopsy under MR guidance
and three under targeted US guidance.
The three lesions identified only at MR
were removed for biopsy under US
guidance. These lesions were not seen
prospectively at screening US. Overall,
16 biopsies were performed as the re-
sult of a positive examination and pro-
duced a cancer yield of 3.5%. Although
the estimated yield of MR was higher
than the other two modalities (the esti-
mated yield of MR was almost three times
that of mammography and five times that
of US), none of the pairwise comparisons
was statistically significant (95% CIs were
MR-US, 0.002%, 0.06%; MR-mam-
mography, 0.005%, 0.052%; and US-
mammography, 0.011%, 0.023%).
Discussion
Our prospective study of 171 women







Analysis Set (n  171)
Age (mean  SD) 45.4  10.3 45.6  10.2
Genetic risk
Family member BRCA1/BRCA2-positive 51 (26.8) 49 (28.7)
Participant had genetic testing 99 (52.1) 91 (53.2)
Confirmed BRCA1-positive 41 (21.6) 37 (21.6)
Confirmed BRCA2-positive 39 (20.5) 36 (21.1)
Menopause status
Premenopausal 88 (46.3) 78 (45.6)
Surgically induced menopause 56 (29.5) 52 (30.4)
Postmenopausal 40 (21.1) 36 (21.1)
Perimenopausal 5 (2.6) 5 (2.9)
History of hormone use 160 (84.2) 145 (84.8)
Breast density
Mostly fat: 10% 16 (8.4) 14 (8.2)
Scattered fibroglandular tissue: 11–50% 45 (23.7) 43 (25.2)
Heterogeneously dense: 51–90% 88 (46.3) 83 (48.5)
Extremely dense: 90% 32 (16.8) 31 (18.1)
Prior benign biopsy 72 (37.9) 64 (37.4)
Prior diagnosis of breast cancer 47 (24.7) 44 (25.7)
Note.—Numbers in parentheses are percentages.
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MR imaging led to the detection of six
cancers. All cancers were detected with
MR, 33% with mammographic, and
17% with US imaging. The added can-
cer yield was associated with a higher
biopsy rate with MR (8.2%) compared
with mammographic (2.3%), and US
(2.3%) imaging.
Our findings are similar to those re-
ported by Kriege et al (20), and by
other prior screening studies comparing
MR with mammography in a high-risk
population (Table 4) (20–27). Overall,
all studies demonstrate that MR has
higher sensitivity in cancer detection at
the cost of a higher biopsy rate. The
recent reports from the Netherlands
(20) and the United Kingdom (21) lend
further support to MR as an effective
screening tool in this patient population.
In the Netherlands study, 45 cancers
were diagnosed in 1909 (2.4%) women
at high risk. The respective sensitivi-
ties of clinical breast examination,
mammography, and MR were 17.9%,
33.3%, and 79.5%. One-half of the
cancers were identified by using MR
alone. Although the specificity of MR
was lower than that of mammography
or clinical breast examination (89.8%,
95.0%, and 98.1%, respectively), the
overall accuracy of MR was signifi-
cantly higher (P  .05). The two con-
trol groups of women at high risk that
did not undergo any form of screening
had more than double the incidence of
positive nodes and micrometastases
(P  .001). Similarly, in the UK study,
MR resulted in an additional cancer
yield of 2.9% and found the sensitivity
of MR to be significantly higher (77%)
when compared with mammography
(40%) in high-risk women (21). The
highest sensitivity (94%) was accom-
plished with a combination of MR and
mammography, although this came at
the cost of lower specificity (77%). Nei-
ther the Netherlands nor the UK study
included US to screen the women en-
rolled.
In our study, US did not identify can-
cers missed at mammography. The one
cancer that was prospectively identified
by using US was also detected at mam-
mography and MR. The lower yield of
US compared with MR is consistent
with prior studies that have evaluated
both MR and US in a single-patient co-
hort (22–24). However, other studies
have reported increased cancer yield by
using US compared with mammography
alone in women with dense breast tissue
(28,29).
Prior studies aimed at screening
women with dense breast tissue by us-
ing US have not included MR. In a re-
cent study of over 6000 asymptomatic
women with dense breasts and normal
mammograms, 23 (cancer yield of
0.3%) malignancies were detected in 21
patients by using US (30). In that study,
the sensitivity of US for the detection of
malignancy was 100% but the specificity
was low at 35%. A more recent study of
1517 women with dense breast tissue
Table 2
Characteristics of Cancers Detected
Patient No.
Patient Characteristics Examination Results Pathologic Results
Age BRCA Status Menopause Status Breast Density Mammography US MR Histology TNM Stage
1 52 BRCA1 Surgical Heterogeneously    IDC T1 N0 M0
2 46 BRCA2 Surgical Heterogeneously    IDC NA
3 46 Unknown Premenopausal Extremely    IDC T0 N0 M0
4 55 BRCA1 Postmenopausal Heterogeneously    IDC T1 N0 M0
5 40 Unknown Surgical Scattered fibroglandular    IDC T1 N0 M0
6 50 Unknown Surgical Scattered fibroglandular    IDC T2 N1 M0
Note.—IDC  infiltrating ductal carcinoma, NA  not available, TNM  tumor-node-metastasis,   positive,   negative.
Table 3
Performance Rates of Mammography, US, and MR





Performed Diagnostic Yield (%)
Additional Cancer
Yield‡
Mammography 17/171 (10) [6%, 15%] 4/171 (2.3) 2/4 (50) 2/171 (1.2) [0, 4] 0/171 (0)
US 15/171 (9) [5%, 14%] 4/171 (2.3) 1/4 (25) 1/171 (0.6) [0, 3] 0/171 (0)
MR 41/171 (24) [18%, 31%] 14/171 (8.2) 6/14 (43) 6/171 (3.5) [1, 7] 4/171 (2.3)
Note.—Numbers in parentheses are percentages, numbers in square brackets are confidence intervals.
* As classified by using BI-RADS 3, 4, or 5.
† Not mutually exclusive. Total biopsies performed as the result of at least one positive exam is 16.
‡ Additional yield is defined as all cancers detected by this examination that were not detected by any other examination.
BREAST IMAGING: Prospective Multi-Institution Screening Study Lehman et al
386 Radiology: Volume 244: Number 2—August 2007
and normal mammograms reported an
additional seven (cancer yield of 0.46%)
cancers diagnosed by using US (31).
Four cancers were detected in high-
risk women and three in women with
average risk. Thus, the added cancer
yield of US in the high-risk group was
1.3%. This study did not include MR. A
large-scale study is currently being con-
ducted through the American College of
Radiology Imaging Network (ACRIN
study 6666, http://www.acrin.org) to
assess the performance of screening US
in women at high risk with dense breast
tissue. That study should provide more
definitive information on the cancer
yield by using US alone in this subgroup
(those with dense breast tissue) of
women at high risk for breast cancer.
There are a few possible explana-
tions for our failure to identify cancers
at US that were occult at mammogra-
phy. First, since MR was not included in
the listed US trials, the sensitivity of US
had no reference standard for compari-
son, in essence acting as its own refer-
ence standard. Likewise, in our study,
MR had the highest sensitivity (100%)
because no independent reference stan-
dard is possible in these trial designs.
Breast density has little effect on MR
sensitivity, and may have performed
better than US in this regard, as US is
challenged in women with fatty breast
tissue (32). In addition, the numbers in
all prior studies are small and the CIs
are wide. Our study included women
with fatty breast tissue and scattered
fibroglandular breast density. Most
prior US screening studies excluded
these women as it is unlikely US will
help confirm occult cancers in women
with fatty breast tissue. It is unlikely
that the quality of equipment was lower
in our study, as the requirements are in
keeping with prior studies. It is ex-
tremely unlikely that the performance
of the US examinations or interpretive
skills of the participating radiologists
were lower in our study compared with
prior studies as all sites are high-volume
breast imaging centers with many years
of experience in high-quality breast US.
This study had limitations. Although
the study clearly demonstrates the fea-
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corporating MR, US, and mammo-
graphic imaging in a one-patient cohort,
the population is small for a screening
study. The small participant number
may also explain why there were no
cases of dual carcinoma in situ detected
during the study. The study did not in-
clude long-term follow-up, and conse-
quently did not provide reference stan-
dard information on participants with
negative MR results. Thus, the variables
of callback and biopsy rates, biopsy
PPVs, and cancer yields are emphasized
rather than sensitivity and specificity
measures, which would be subject to
verification bias in this study setting.
Our study performed a single round of
screening. This can bias our results by
reporting prevalent malignancies for an
examination that has been previously
used by participants (mammography)
and comparing them with incident ma-
lignancies found during an examination
that is new to participants (US and MR).
In conclusion, our multi-institutional
study further supports MR as an impor-
tant complement to mammography in
screening women at high risk for breast
cancer. At this time, further studies are
needed to more clearly address the po-
tential role of US in this patient popula-
tion before it can be promoted as a rea-
sonable alternative to MR for screening
women at high risk.
Acknowledgments: We thank Jean Cormack,
PhD (Brown University), for statistical analytical
support and Sue Peacock, MSc (University of
Washington), for administrative support.
References
1. Genetics of breast and ovarian cancer




2. Breast Cancer Facts & Figures 2005–2006.
American Cancer Society Web site. http://
www.cancer.org/downloads/STT/CAFF2005-
BrF.pdf. Accessed February 1, 2006.
3. Hartmann LC, Sellers TA, Schaid DJ, et al.
Efficacy of bilateral prophylactic mastectomy
in BRCA1 and BRCA2 gene mutation carri-
ers. J Natl Cancer Inst 2001;93:1633–1637.
4. Meijers-Heijboer H, van Geel B, van Putten
WL, et al. Breast cancer after prophylactic
bilateral mastectomy in women with a
BRCA1 or BRCA2 mutation. N Engl J Med
2001;345:159–164.
5. Rebbeck TR. Prophylactic oophorectomy in
BRCA1 and BRCA2 mutation carriers. Eur J
Cancer 2002;38(suppl 6):S15–S17.
6. Rebbeck TR, Friebel T, Lynch HT, et al.
Bilateral prophylactic mastectomy reduces
breast cancer risk in BRCA1 and BRCA2
mutation carriers: the PROSE Study Group.
J Clin Oncol 2004;22:1055–1062.
7. Kauff ND, Satagopan JM, Robson ME, et
al. Risk-reducing salpingo-oophorectomy
in women with a BRCA1 or BRCA2 muta-
tion. N Engl J Med 2002;346:1609–1615.
8. Rebbeck TR, Levin AM, Eisen A, et al.
Breast cancer risk after bilateral prophylac-
tic oophorectomy in BRCA1 mutation carri-
ers. J Natl Cancer Inst 1999;91:1475–1479.
9. Brekelmans CT, Seynaeve C, Bartels CC, et
al. Effectiveness of breast cancer surveil-
lance in BRCA1/2 gene mutation carriers
and women with high familial risk. J Clin
Oncol 2001;19:924–930.
10. Warner E. Intensive radiologic surveillance:
a focus on the psychological issues. Ann On-
col 2004;15(suppl 1):I43–I47.
11. Narod SA, Brunet JS, Ghadirian P, et al.
Tamoxifen and risk of contralateral breast
cancer in BRCA1 and BRCA2 mutation
carriers: a case-control study. Hereditary
Breast Cancer Clinical Study Group. Lancet
2000;356:1876–1881.
12. Easton DF, Ford D, Bishop DT. Breast and
ovarian cancer incidence in BRCA1-muta-
tion carriers. Breast Cancer Linkage Consor-
tium. Am J Hum Genet 1995;56:265–271.
13. Smith RA, Cokkinides V, Eyre HJ. American
Cancer Society guidelines for the early de-
tection of cancer, 2004. CA Cancer J Clin
2004;54:41–52.
14. Regence. The Regence Group Medical Pol-
icy, Radiology Section: MR of the Breast.
The Regence Group Web site. http://www
.regence.com/trgmedpol/radiology/rad43
.html. Accessed February 2, 2006.
15. Aetna. Aetna Clinical Policy Bulletin: Breast
MR. Aetna Web site. http://www.aetna.com
/cpb/data/CPBA0105.html. Accessed Febru-
ary 2, 2006.
16. BlueCross BlueShield. Magnetic resonance im-
aging of the breast in screening women consid-
ered to be at high genetic risk of breast cancer.
http://www.bcbst.com/mpmanval/whstart
.com. Accessed February 2, 2006.
17. Anton-Culver H, Ziogas A, Bowen D, et al.
The Cancer Genetics Network: recruitment
results and pilot studies. Community Genet
2003;6:171–177.
18. Berry DA, Iversen ES Jr, Gudbjartsson DF,
et al. BRCAPRO validation, sensitivity of ge-
netic testing of BRCA1/BRCA2, and preva-
lence of other breast cancer susceptibility
genes. J Clin Oncol 2002;20:2701–2712.
19. American College of Radiology. ACR BI-
RADS: mammography. In: ACR Breast Im-
aging Reporting and Data System, Breast Im-
aging Atlas. Reston, Va: American College of
Radiology, 2003.
20. Kriege M, Brekelmans CT, Boetes C, et al.
Efficacy of MR and mammography for
breast-cancer screening in women with a
familial or genetic predisposition. N Engl
J Med 2004;351:427–437.
21. Leach MO, Boggis CR, Dixon AK, et al.
Screening with magnetic resonance imaging
and mammography of a UK population at
high familial risk of breast cancer: a prospec-
tive multicentre cohort study (MARIBS).
Lancet 2005;365:1769–1778.
22. Kuhl CK, Schmutzler RK, Leutner CC, et al.
Breast MR imaging screening in 192 women
proved or suspected to be carriers of a
breast cancer susceptibility gene: prelimi-
nary results. Radiology 2000;215:267–279.
23. Warner E, Plewes DB, Hill KA, et al. Surveil-
lance of BRCA1 and BRCA2 mutation carri-
ers with magnetic resonance imaging, ultra-
sound, mammography, and clinical breast
examination. JAMA 2004;292:1317–1325.
24. Podo F, Sardanelli F, Canese R, et al. The
Italian multi-center project on evaluation of
MR and other imaging modalities in early
detection of breast cancer in subjects at high
genetic risk. J Exp Clin Cancer Res 2002;21:
115–124.
25. Tilanus-Linthorst MM, Obdeijn IM, Bartels
KC, de Koning HJ, Oudkerk M. First experi-
ences in screening women at high risk for
breast cancer with MR imaging. Breast Can-
cer Res Treat 2000;63:53–60.
26. Morris EA, Liberman L, Ballon DJ, et al. MR
of occult breast carcinoma in a high-risk pop-
ulation. AJR Am J Roentgenol 2003;181:
619–626.
27. Lehman CD, Blume JD, Weatherall P, et al.
Screening women at high risk for breast can-
cer with mammography and magnetic reso-
nance imaging. Cancer 2005;103:1898–
1905.
28. Kolb TM, Lichy J, Newhouse JH. Occult can-
cer in women with dense breasts: detection
with screening US—diagnostic yield and tu-
mor characteristics. Radiology 1998;207:
191–199.
29. Kolb TM, Lichy J, Newhouse JH. Compari-
son of the performance of screening mam-
mography, physical examination, and breast
US and evaluation of factors that influence
them: an analysis of 27,825 patient evalua-
tions. Radiology 2002;225:165–175.
30. Buchberger W, DeKoekkoek-Doll P,
Springer P, Obrist P, Dunser M. Incidental
findings on sonography of the breast: clinical
significance and diagnostic workup. AJR
Am J Roentgenol 1999;173:921–927.
31. Crystal P, Strano SD, Shcharynski S, Koretz
MJ. Using sonography to screen women with
mammographically dense breasts. AJR Am J
Roentgenol 2003;181:177–182.
32. Bluemke DA, Gatsonis CA, Chen MH, et al.
Magnetic resonance imaging of the breast
prior to biopsy. JAMA 2004;292:2735–2742.
BREAST IMAGING: Prospective Multi-Institution Screening Study Lehman et al
388 Radiology: Volume 244: Number 2—August 2007
